2018
False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab
Chen PP, Tormey CA, Eisenbarth SC, Torres R, Richardson SS, Rinder HM, Smith BR, Siddon AJ. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab. American Journal Of Clinical Pathology 2018, 151: 154-163. PMID: 30307483, DOI: 10.1093/ajcp/aqy129.Peer-Reviewed Original ResearchConceptsHealthy donor bloodAlemtuzumab treatmentDonor bloodBone marrowFlow cytometryLight chain restrictionT-cell prolymphocytic leukemiaB-cell neoplasmsLight chain clonalityFlow cytometry analysisAutoimmune diseasesHematologic malignanciesImmunophenotypic analysisChain restrictionAlemtuzumabT cellsB cellsProlymphocytic leukemiaImmunoglobulin G1PatientsMonoclonal antibodiesCytometry analysisSimilar findingsBloodClonal restriction
1993
Reticulated platelets in the evaluation of thrombopoietic disorders.
Rinder HM, Munz UJ, Ault KA, Bonan JL, Smith BR. Reticulated platelets in the evaluation of thrombopoietic disorders. Archives Of Pathology & Laboratory Medicine 1993, 117: 606-10. PMID: 8503732.Peer-Reviewed Original ResearchConceptsImmune platelet destructionImmune thrombocytopeniaPlatelet destructionNormal subjectsImmune thrombocytopenic purpuraThird of patientsSubset of patientsPlatelet determinationAbsence of megakaryocytesPlatelet-associated IgGChemotherapy-induced thrombocytopeniaInvasive diagnostic testsPeripheral blood plateletsFlow cytometric assayIgG levelsThrombocytopenic purpuraReticulated plateletsImmune destructionPlatelet valuesPatientsPlatelet IgGBone marrowThrombocytopeniaIgG dataLaboratory diagnosis
1991
Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E, Reichert T, Blythman H, Bouloux C, Rappeport J, Burakoff S, Weinstein H. Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies. Blood 1991, 78: 2139-2149. PMID: 1717080, DOI: 10.1182/blood.v78.8.2139.2139.Peer-Reviewed Original ResearchConceptsAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patientsSelective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991, 78: 2139-2149. DOI: 10.1182/blood.v78.8.2139.bloodjournal7882139.Peer-Reviewed Original ResearchAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patients
1988
REGULATION OF CYTOTOXIC T LYMPHOCYTE-MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW
Bierer B, Emerson S, Antin J, Maziarz R, Rappeport J, Smith B, Burakoff A. REGULATION OF CYTOTOXIC T LYMPHOCYTE-MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW. Transplantation 1988, 46: 835-839. PMID: 3061078, DOI: 10.1097/00007890-198812000-00009.Peer-Reviewed Original ResearchConceptsGraft rejectionHuman allogeneic bone marrow transplantationT cell-depleted marrowAllogeneic bone marrow transplantationClass I major histocompatibility complex antigensMajor histocompatibility complex antigensLymphocyte function-associated antigen-1Bone marrow transplantationFunction-associated antigen-1Cytotoxic T lymphocytesAnti-CD3 mAbHistocompatibility complex antigensBone marrow progenitor cellsMHC class IMarrow progenitor cellsNumber of mAbsBMT patientsCTL activityEffector cellsMarrow transplantationRecipient originT cellsT lymphocytesComplex antigensBone marrow
1987
Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients.
Daley J, Rozans M, Smith B, Burakoff S, Rappeport J, Miller R. Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients. Blood 1987, 70: 960-4. PMID: 3307954, DOI: 10.1182/blood.v70.4.960.bloodjournal704960.Peer-Reviewed Original ResearchConceptsT cell-depleted bone marrowT cell frequenciesUntreated marrowT cellsBone marrowCell frequencyFunctional T cell compartmentBone marrow transplant recipientsDonor T cellsMonoclonal antibodies Leu-1Marrow transplant recipientsReactive T cellsT cell compartmentT lymphocyte precursorsCompetent T lymphocytesTransplant recipientsMarrow transplantationT lymphocytesLymphocyte precursorsLeu-1Neoplastic cellsMarrowPatientsRecipientsTransplantationRetarded Recovery of Functional T Cell Frequencies in T Cell–Depleted Bone Marrow Transplant Recipients
Daley J, Rozans M, Smith B, Burakoff S, Rappeport J, Miller R. Retarded Recovery of Functional T Cell Frequencies in T Cell–Depleted Bone Marrow Transplant Recipients. Blood 1987, 70: 960-964. DOI: 10.1182/blood.v70.4.960.960.Peer-Reviewed Original ResearchT cell-depleted bone marrowT cell frequenciesUntreated marrowT cellsBone marrowCell frequencyFunctional T cell compartmentBone marrow transplant recipientsDonor T cellsMonoclonal antibodies Leu-1Marrow transplant recipientsReactive T cellsT cell compartmentT lymphocyte precursorsCompetent T lymphocytesTransplant recipientsMarrow transplantationT lymphocytesLymphocyte precursorsLeu-1Neoplastic cellsMarrowPatientsRecipientsTransplantation
1985
EFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA
Smith BR, Guinan EC, Parkman R, Ferrara J, Levey RH, Nathan DG, Rappeport JM. EFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA. Transplantation 1985, 39: 671-672. PMID: 3890295, DOI: 10.1097/00007890-198506000-00020.Peer-Reviewed Original Research